The findings of the study, which are currently being developed for SonoThera’s Duchenne Muscular Dystrophy (DMD) treatment, demonstrate the capability of Ultrasound-Mediated Delivery technology to deliver genetic drugs. This technology enables full-length dystrophin protein expression in skeletal, cardiac, and diaphragm muscles in mouse and non-human primate (NHP) models.
SonoThera, a biotechnology company dedicated to treating the root cause of human diseases through developing the next generation of genetic medicines, today announced it will present new data at the 28th annual American Society of Gene and Cell Therapy (ASGCT) meeting being held May 13-17th in New Orleans, Louisiana.
“We’re pleased to be presenting new data at ASGCT highlighting the potential of ultrasound mediated delivery in solving the key challenges in genetic medicine,” said Kenneth Greenberg, PhD, CEO of SonoThera. “This data continues to demonstrate our unique capabilities, including targeted full-length human dystrophin expression in muscle, and delivering oversized genetic payloads in a durable, safe, redosable and noninvasive manner. We look forward to sharing our latest data at this year’s annual meeting.”
Learn more: Ultrasound-Mediated Delivery (UMD)
